Cannabis Law Report

AUGUST 3, 2021

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

FloridaMarijuana.net

AUGUST 13, 2018

There are a variety of treatment options to help patients cope with and heal from anxiety disorders. Even mainstream media has delved into the medicinal properties of cannabis and the science-based culture that cannabis heals. Cannabis has potential for the treatment of PTSD and substance use disorders.

Marijuana 145

Marijuana Patients Clinical Trials Conditions 145

Veriheal

JULY 16, 2020

Despite the novelty of its drug policy findings, the document has gone largely unnoticed by reform advocates and the media. from doing any research about the efficacy or risks of these treatment options. federal government’s policies have blocked externally valid, randomized clinical trials on the effects of cannabis,” the report says.

Research and Development 97

Research and Development Clinical Trials Treatment Compliance 97

Cannabis Law Report

SEPTEMBER 29, 2021

ANANDA Scientific Media Relations | Christopher Moore | 813 326 4265 | media@anandascientific.com. . & LOS ANGELES–(BUSINESS WIRE)– ANANDA Scientific Inc. , An Investigational New Drug (IND) application is being submitted to the U.S.

Clinical Trials 40

Clinical Trials Medicine Treatment Research and Development 40

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Info

OCTOBER 11, 2019

Cannabis & Dementia: New Study Explores Pot’s Potential for Treatment. In the decades since the medical marijuana movement began in earnest in the 1970s, cannabis has been anecdotally touted as an effective treatment for a variety of illnesses, including those impacting brain function, such as seizures, anxiety and depression.

Treatment 45

Treatment Clinical Trials Cannabinoids Cannabis 45

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. Media: media@mymd.com. in the blood. 646) 421-9523.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Cannabis Law Report

JUNE 30, 2021

LONDON–(BUSINESS WIRE)– Fourfive , the CBD and nutrition brand loved by athletes and those leading an active lifestyle, today called on the UK’s sports governing bodies to stop sitting if on the fence and conduct clinical trials into the effectiveness of CBD and medicinal cannabis in professional sport. fourfive.com.

Medicine 75

Medicine Clinical Trials CBD Sleep 75

Cannabis Law Report

AUGUST 21, 2019

Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said current treatments for adults suffering severe symptoms were “not cost effective”. If you wish to re-publish this story please do so with following accreditation. AUTHOR: Mark Taylor.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

NOVEMBER 23, 2021

The new patent, US Patent No 11,180,517, covers methods of treating treatment-resistant depression (TRD) with crystalline psilocybin as well as with oral dosage forms of crystalline psilocybin with an excipient. This is COMPASS’s 10 th patent overall, with five now granted in the US, two in the UK, one in Germany and two in Hong Kong.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease. For media inquiries please contact: Michael Sharp. Orphan Drug Designation?

DEA 51

DEA Clinical Trials THC Research and Development 51

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Available at: www.fda.gov/media/131878/download. 2021.06.005.

CBD 144

CBD Seed-To-Sale Food Access 144

CannaMD

MARCH 8, 2021

Prohibiting a medical marijuana treatment center from dispensing marijuana that exceeds a certain potency of tetrahydrocannabinol [p. Revising a provision relating to the potency of tetrahydrocannabinol in edibles dispensed by a medical marijuana treatment center [p.1, 2, line 32]. 2, line 38]. 1, line 12]. 2, line 26]. 2, line 29].

THC 116

THC Research and Development Treatment Patients 116

CannaMD

NOVEMBER 6, 2019

Perhaps the commercialization of marijuana and the favorable media coverage surrounding the health effects of marijuana are fostering such a perception. Another finding of the study was that there was minimal crossover between these treatment options, with only three percent of respondents using both marijuana and opioids. Get Started.

Marijuana 107

Marijuana Patients Clinical Trials Data 107

Cannabis Law Report

OCTOBER 5, 2021

Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions. An evaluation of the therapeutic value, benefits and risks of methylenedioxymethamphetamine (MDMA) and psilocybin for the treatment of mental, behavioural or developmental disorders.

Treatment 52

Treatment Conditions Medicine Clinical Trials 52

Cannabis Law Report

JULY 6, 2021

Johnson’s primary area of research expertise is the psychopharmacology of medications for treating addictions, and he is well known in the field for his discovery that topiramate, a gamma-aminobutyric acid (GABA) facilitator and glutamate antagonist, an effective treatment for alcoholism. ” About Ehave, Inc. Ehave, Inc.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

OCTOBER 22, 2021

Medicines and Healthcare products Regulatory Agency (the “ MHRA ”), Small Pharma has been granted an Innovation Passport Designation for SPL026, the lead product candidate from its pipeline of N,N-dimethyltryptamine (“ DMT ”) assisted therapies for the treatment of major depressive disorder (“ MDD ”). About Small Pharma.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

DECEMBER 9, 2021

Nue Life launched its proprietary nue.app on November 8 to increase access to psychedelic treatment as a catalyst for lasting change. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. MIAMI , Dec. ” About Nue Life.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. US Provisional Patent Filed. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

JANUARY 12, 2022

. “Gb Sciences has established a pipeline of patent-protected combination therapies for the treatment of medical conditions affecting hundreds of millions of people,” said Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. Media Contact. In addition, Gb Sciences has 12 U.S. 31, 2021.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Alchimia

JANUARY 25, 2022

At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. While this research is certainly worth celebrating, the reality behind the message can be easily misunderstood in this age of social media. Cannabis as a treatment for COVID-19 infection.

Research and Development 98

Research and Development Terpenes CBD Treatment 98

The Cannigma

JULY 1, 2022

What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? Preclinical studies involve exposing cells and animals to treatments to see if there are indications that the treatment could be worth evaluating in humans. The cannabis research problem.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

JANUARY 13, 2020

Commence clinical program in PTSD. Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia. Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

Cannabis Law Report

NOVEMBER 16, 2019

Scheme (SAS), Authorised Prescriber Scheme and clinical trials; (b) the suitability of the Pharmaceutical Benefits Scheme for subsidising patient access to medicinal cannabis products; (c) the interaction between state and territory authorities and the Commonwealth, including overlap and variation between. Media Releases.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is a limited liability corporation formed under the laws of Arizona , which operates 10 ketamine infusion treatment clinics, across Arizona , Colorado , Florida , Illinois , Minnesota , Nevada , Texas , and Washington. Transaction Highlights.

Treatment 52

Treatment Media Research and Development Patients 52

The Blunt Truth

AUGUST 13, 2019

In each instance, the companies were selling products with flagrant disease-related claims that the FDA had not approved for the treatment or prevention of any ailments. 331(ll)), the FDA prohibits the sale of products containing an ingredient that has been treated as a drug or involved in clinical trials, without prior FDA approval.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Media coverage of the paper led to a new stigma and political pressure ended the Spain MDMA study. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

SEPTEMBER 24, 2019

Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. These treatments can be prescribed only by specialist doctors in a limited number of circumstances where other medicines have failed.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Media: Liz Melone. CAMBRIDGE, Mass.–(BUSINESS 212-362-1200.

Clinical Trials 40

Clinical Trials Research and Development Data Patients 40

Cannabis Law Report

DECEMBER 9, 2021

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. Media Contact: media@mindmed.co. Investor Contact: ir@mindmed.co.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Topical 40

Cannabis Law Report

OCTOBER 17, 2019

The introduction of these protocols will take the form of clinical trials and research that will include the usage of specific strains of cannabis that aid in chronic pain and cancer treatments. Media Relations. Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

Cannabis Law Report

NOVEMBER 24, 2019

Future studies will explore psilocybin’s effectiveness as a new therapy for opioid addiction, Alzheimer’s disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), anorexia nervosa, and alcohol use in people with major depression. December 3, 2019. December 4, 2019.

Therapy 59

Therapy Treatment Medicine Clinical Trials 59

Veriheal

JUNE 24, 2021

The NIH has been considered the largest public funder of medical research and media reports state that the NIH is persistent in supporting studies that are “conceptualizing psychedelics primarily as drugs of abuse”. He also stated that he thinks “over the course of the next year, we’re going to want to have a hard look at this”. .

Research and Development 52

Research and Development Clinical Trials Treatment Access 52

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.

Clinical Trials 40

Clinical Trials Research and Development Data Medicine 40